We aimed to determine the incidence, treatment regimen, and treatment outcomes (including progression-free survival and overall survival) of gynecologic carcinosarcoma, a rare, aggressive, and understudied gynecologic malignancy. This retrospective review included all patients with gynecologic cancers diagnosed and treated at a single tertiary care comprehensive cancer center between January 2012 and May 2021. A total of 2116 patients were eligible for review, of which 84 cases were identified as carcinosarcoma: 66 were uterine (5.2% of uterine cancers), 17 were ovarian (3.6% of ovarian cancers), 1 was cervical (0.28% of cervical cancers), and 1 was untyped. Of the patients, 76.2% presented advanced-stage disease (stage III/IV) at the time of diagnosis. Minority patients were more likely to present with stage III/IV (p< 0.0001). The majority of patients underwent surgical resection followed by systemic chemotherapy with carboplatin and paclitaxel. The median PFS was 7.5 months. Of the patients, 55% were alive 1 year after diagnosis, and 45% were alive at 5 years. In the studied population, minorities were more likely to present with more advanced disease. The rate of gynecologic carcinosarcomas was consistent with historical reports.
本研究旨在确定妇科癌肉瘤这一罕见、侵袭性强且研究不足的妇科恶性肿瘤的发病率、治疗方案及治疗结局（包括无进展生存期和总生存期）。本回顾性研究纳入了2012年1月至2021年5月期间在某三级综合癌症中心诊断和治疗的所有妇科癌症患者。共2116例患者符合纳入标准，其中84例被确认为癌肉瘤：子宫癌肉瘤66例（占子宫癌的5.2%），卵巢癌肉瘤17例（占卵巢癌的3.6%），宫颈癌肉瘤1例（占宫颈癌的0.28%），另有1例未分型。76.2%的患者在诊断时已处于晚期（III/IV期）。少数族裔患者更易出现III/IV期疾病（p<0.0001）。大多数患者接受了手术切除，随后接受卡铂和紫杉醇的全身化疗。中位无进展生存期为7.5个月。55%的患者在诊断后存活1年，45%的患者存活5年。在研究人群中，少数族裔患者更易出现更晚期的疾病。妇科癌肉瘤的发生率与历史报告一致。
Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience
肿瘤(癌症)患者之家